Research on Incentive Mechanism of Repurposing Drugs for Rare Diseases

Abstract

Objective To improve the system of accelerated review and approval, and to speed up the development and marketing of repurposing drugs for rare diseases in China. Methods The relevant concepts of rare diseases and the definition of drug repurposing were introduced so as to sort out the advantages and disadvantages of the research and development of drug repurposing for rare diseases. Then, the incentive mechanisms of the research and development of drug repurposing for rare diseases in China and abroad were compared. Results and Conclusion Some suggestions on improving the incentive mechanism of repurposing drugs for rare diseases such as policy support for talents introduction, capital investment, and innovation capabilities are proposed. Besides, the government should further improve policies for the research and development of repurposing drugs for rare diseases, which can gradually narrow the gap between the research and innovation of drug repurposing in developed countries, thus benefiting the patients of rare diseases.

Keywords

rare disease / drug repurposing / incentive mechanism / innovation ability

References

[1] Jin Xiaowei, Chen Li. Orphan drug development in China - turning challenges into opportunities[J]. Intractable & Rare Diseases Research, 2016, 5 (4): 308-313.

[2] Jules JB. Rare Diseases and Orphan Drugs[M]. San Diego: Academic Press, 2014: 3-8.

[3] Drummond MF, Wilson DA, Panos K, et al. Assessing the economic challenges posed by orphan drugs[J]. International Journal of Technology Assessment in Health Care, 2007, 23 (1): 36-42.

[4] The General Office of the Central Committee of CPC. Opinions on Deepening the Reform of Review and Approval System and Encouraging the Innovation of Medical Products and Devices[Z]. 2017.

[5] Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies[J]. Nature Reviews Drug Discovery, 2015, 14 (7): 475-486.

[6] Chow SC. Innovative approach for rare diseases drug development [A]. DIA Regional Annual Meeting[C]. Washington, DC: Chapman and Hall/CRC, 2020.

[7] Board on Health Sciences Policy, Institute of Medicine. Institute of Medicine. Drug repurposing and repositioning: Workshop summary [A]. Roundtable on Translating Genomic-Based Research for Health[C]. Washington, DC: National Academies Press, 2014.

[8] Li Lele, He Xiaotong, Chen Xiangyu, et al. Research on current situation and optimized path of drug use system of rare diseases in China[J]. China Health Insurance, 2022, 23 (9): 116-119.

[9] Li Yayuan, Ding Hong, Su Xia. Analysis and prospect of status of orphan drug research[J]. Journal of International Pharmaceutical Research, 2017, 44 (2): 107-111.

[10] Shin E, Lee Y, Kim S, et al. Drug signature-based finding of additional clinical use of LC28-0126 for neutrophilic bronchial asthma[J]. Scientific Report, 2015, 6 (8): 14-15.

[11] Franco P. Orphan drugs: The regulatory environment[J]. Drug Discovery Today, 2013, 18 (3/4): 163-172.

[12] Sharma A, Jacob A, Tandon M, et al. Orphan drug: Development trends and strategies[J]. Journal of Pharmacy and Bioallied Sciences, 2010, 2 (4): 290-299.

[13] Wang Hong, Wu Zhiang. Incentives for orphan drugs R&D in Europe and America and the enlightenment for China[J]. Chinese Journal of New Drugs, 2015, 24 (15): 1681-1685+1693.

[14] FDA. Rare diseases at FDA[EB/OL]. (2022-12-13) [2023-05-28]. https://www.fda.gov/patients/rare-diseasesfda#:-:text=The%20Orphan%20Drug%20Act%20is%20a%20law%20passed,such%20designation%20if%20the%20drug%20meets%20specific%20criteria.

[15] FDA. Introduction to the office of orphan products development (OOPD)[EB/OL]. (2017-05-15)[2023-05- 28]. https://www.fda.gov/media/128018/download.

[16] Crockett SD, Schectman R, Stürmer T, et al. Topiramate use does not reduce flares of inflammatory bowel disease[J]. Digestive Diseases and Sciences, 2014, 59 (7): 1535-1543.

[17] Wang Xue, Zhao Cong, Xu Shuhong, et al. Analysis of the rare disease drugs availability in China[J]. China Journal of Clinical Pharmacology, 2021, 37 (8): 7.

[18] FDA. FDA search orphan drug designations and approvals[EB/OL]. (1983-01-01)[2023-05-28]. https://www.accessdata.fda.gov/scrips/opdlisting/oopd/index.cfm.

[19] Cowell JK, Hu T. Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: Implications for optimized treatment[J]. Cancer Drug Resistance, 2021, 4 (3): 607-619.

[20] FDA. FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement[EB/OL]. (2022-08-29)[2023-05-28]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pemigatinib-relapsed-or-refractorymyeloidlymphoid-neoplasms-fgfr1-rearrangement.

[21] Leukemia & Lymphoma Society. Polycythemia vera facts. No. 13.[EB/OL]. (2012-06)[2023-05-28]. www.lls.org/content/nationalcontent/resourcecenter/freeeducationmaterials/mpd/pdf/polycythemiavera.pdf.

[22] Raedler LA. Jakafi (Ruxolitinib): First FDA-approved medication for the treatment of patients with polycythemia vera[J]. American Health & Drug Benefits, 2015, 8: 75- 79.

[23] Jacobsohn DA, Vogelsang GB. Acute graft versus host disease[J]. Orphanet Journal of Rare Diseases, 2007, 2: 35.

[24] FDA. Project Orbis, a framework for concurrent submission and review of oncology products[EB/OL]. (2023-11-01)[2023-05-28]. https://www.fda.gov/aboutfda/oncology-center-excellence/project-orbis.

[25] FDA. FDA approves ruxolitinib for chronic graft-versushost disease[EB/OL]. (2021-09-22)[2023-05-28]. https://www.fda.gov/drugs/resources-information-approveddrugs/fda-approves-ruxolitinib-chronic-graft-versushost-disease#:-:text=On%20September%2022%2C%202021%2C%20the%20Food%20and%20Drug,adult%20and%20pediatric%20patients%2012%20years%20and%20older.

[26] NHC. Notice on Issuing the First BatchofRareDiseasesCatalogue[EB/OL].(2018-06-08)[2023-05-28]. http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.

[27] Fu Suying. Suggestions on clarifying the criteria and procedure of identifying rare disease[N]. China Securities Journal, 2023-03-11 (A 11).

[28] Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: Progress, challenges and recommendations[J]. Nature Review Drug Discovery, 2019, 18 (1): 41-58.

[29] Markey KA, Ottridge R, Mitchell JL, et al. Assessing the efficacy and safety of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor (AZD4017) in the idiopathic intracranial hypertension drug trial, IIH: DT: Clinical methods and design for a phase II randomized controlled trial[J]. JMIR Research Protocols, 2017, 6 (8): 181.

[30] Bai Hua, Zhang Shuyang. Suggestions for promoting domestic clinical trials of medicinal products for rare diseases[J]. International Pharmaceutics Research, 2019, 46 (9): 6.

[31] Chen Ling, Liu Yanhong, Zou Xu, et al. Overview of the latest progress of global new drug research in 2015[J]. Chinese Journal of New Drugs, 2016, 25 (6): 601-621+638.